Account Info
Log Out
Log in to access Online Inquiry
Back to the Top

Medtronic - Time to call the doctor?

JP_mykayaplus wrote a column · May 29, 2023 10:56
Medtronic - Time to call the doctor?
Medtronic released its Q4'23 results and share prices tumbled after that.
It joins plenty of companies that saw their share prices tank after providing guidance below Wall Street estimates.
But what are the few things that you need to know about the company on top of the disappointing guidance?
1. Company operating in the medical device sector
Medtronic is a company that have multiple products in the healthcare sector.
Source: Medtronic Q4'23 earnings presentation
Source: Medtronic Q4'23 earnings presentation
Its products are widely used for diabetes, cardiovascular, medical-surgical, and neuroscience.
As there are technology breakthroughs in surgery, there is a need for Medtronic to innovate and launch new products to remain relevant.
Source: Medtronic Q4'23 earnings presentation
Source: Medtronic Q4'23 earnings presentation
2. Lucrative but competitive business.
Medtronic - Time to call the doctor?
The medical device business is highly lucrative. The gross margin of Medtronic for FY 23 is 65.7%.
However, it is not the only company operating in this segment. Some notable competitors include $Johnson & Johnson(JNJ.US)$MedTech, $SIEMENS HEALTHINEERS AG UNSPON ADR EACH REP 0.50 ORD SHS(SMMNY.US)$, $Royal Philips(PHG.US)$.
3. Revenue dropped mainly due to guidance
Even though the medical device business might be an evergreen and profitable one, it is not spared by worrying economic climate.
For its latest quarter, revenue was lower due to slower predicted procedure and supply recovery.
As for guidance, due to unfavorable foreign currency impact, Medtronic is lowering its full-year non-GAAP EPS guidance to USD 5.25 - USD 5.30.
It did not sit well with Wall Street, hence the drop in stock prices.
Visit for more investing-related content!
The information available in this article/report/analysis is for sharing and education purposes only. This is neither a recommendation to purchase or sell any of the shares, securities, or other instruments mentioned; nor can it be treated as professional advice to buy, sell or take a position in any shares, securities, or other instruments. If you need specific investment advice, please consult the relevant professional investment advice and/or for study or research only.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Sign in to post a comment
    Co-founder, chief editor and analyst of